Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator

Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell‐killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. We developed a population pharmacokinetics (PKs) model for mezigdomide in healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Fan, Liu, Liangang, Gaudy, Allison, Wang, Xiaomin, Carayannopoulos, Leon, Pourdehnad, Michael, Lamba, Manisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583261/
https://www.ncbi.nlm.nih.gov/pubmed/37705327
http://dx.doi.org/10.1002/psp4.13024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583261/
https://www.ncbi.nlm.nih.gov/pubmed/37705327
http://dx.doi.org/10.1002/psp4.13024

Ejemplares similares